• Publications
  • Influence
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
Ebola virus (EBOV) entry requires the surface glycoprotein (GP) to initiate attachment and fusion of viral and host membranes. Here we report the crystal structure of EBOV GP in its trimeric,Expand
  • 559
  • 71
  • PDF
Fc receptor but not complement binding is important in antibody protection against HIV
Most successful vaccines elicit neutralizing antibodies and this property is a high priority when developing an HIV vaccine. Indeed, passively administered neutralizing antibodies have been shown toExpand
  • 749
  • 42
Structural definition of a conserved neutralization epitope on HIV-1 gp120
The remarkable diversity, glycosylation and conformational flexibility of the human immunodeficiency virus type 1 (HIV-1) envelope (Env), including substantial rearrangement of the gp120 glycoproteinExpand
  • 777
  • 38
  • PDF
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models suggest that high antibody concentrations are required. This is a major potential hurdle forExpand
  • 505
  • 16
  • PDF
Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120
Anti-HIV Antibody Constraints Despite significant efforts, an effective vaccine against the HIV-1 virus remains elusive. A site on the HIV-1 gp120 envelope glycoprotein that binds to the CD4 receptorExpand
  • 285
  • 13
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
To guide vaccine design, we assessed whether human monoclonal antibodies (MAbs) b12 and b6 against the CD4 binding site (CD4bs) on HIV-1 gp120 and F240 against an immundominant epitope on gp41 couldExpand
  • 237
  • 12
  • PDF
An Affinity-Enhanced Neutralizing Antibody against the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 gp41 Recognizes an Epitope between Those of 2F5 and 4E10
ABSTRACT The membrane-proximal external region (MPER) of human immunodeficiency virus type 1 (HIV-1) gp41 bears the epitopes of two broadly neutralizing antibodies (Abs), 2F5 and 4E10, making it aExpand
  • 169
  • 12
  • PDF
Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro
ABSTRACT A major unknown in human immunodeficiency virus (HIV-1) vaccine design is the efficacy of antibodies in preventing mucosal transmission of R5 viruses. These viruses, which use CCR5 as aExpand
  • 675
  • 9
Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1
ABSTRACT The human antibody immunoglobulin G1 (IgG1) b12 neutralizes a broad range of human immunodeficiency virus-type 1 (HIV-1) isolates in vitro and is able to protect against viral challenge inExpand
  • 185
  • 8
Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers
Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but important goal of HIV vaccine research, especially after the recent failure of the leading T cell basedExpand
  • 480
  • 7
  • PDF